

Review of over 15 years post-marketing safety surveillance spontaneous data for the human rotavirus vaccine (*Rotarix*) on intussusception

Journal: Drug Safety

Authorship: Tina Singh¹, Frédérique Delannois¹, François Haguinet¹, Lifeter Yenwo Molo¹

Affiliations:





¹GSK, Avenue Fleming 20, 1300 Wavre, Belgium

Corresponding author:

Tina Singh

tina.x.singh@gsk.com

Electronic supplementary material 5 Significance area for the equality test of observed and expected incidences within 30 days (day 0–day 29) after the second dose according to the reported fraction of events for (a) worldwide, (b) Europe, (c) the United States, and (d) Japan



— BCL1 — BCL3 — Expected --- 95%CI
— BCL4

BCL1, Brighton Collaboration Working Group level 1; BCL3, Brighton Collaboration Working Group levels 1–3; BCL4, Brighton Collaboration Working Group levels 1–4; Low Ref. – High Ref., range of expected cases according to background incidence rates

(high ref is out of scale on all panels); 95% CI, 95 percent confidence interval. Total number of doses was 319,695,721 for worldwide, 16,029,101 for Europe, 10,945,330 for the United States, and 3,406,093 for Japan.